Catalyst Pharmaceuticals Reports Record First Quarter 2023
Reports Record Total Revenues of $85.4 Million for Q1 2023 Delivers Revenue Growth of 98%, a Record Increase YoY GAAP EPS Diluted of $0.26 Per Share; a...
Patrickj Mcenany Dydo Pharma Devices Agency Company Nasdaq Development Expenses Catalyst Pharmaceuticals Inc
Source: globenewswire.com